Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting

Executive Summary

FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.

You may also be interested in...



Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill

US FDA would need additional appropriations to cover all activities contemplated in the legislation – and the bill appears to need a pay-for because it increases the deficit.

PDUFA VI: 'Building Trust' Is Theme Of FDA-Industry Negotiations

Major achievements of latest drug user fee agreement include focus on drug development cycle, more review time and pilot programs, FDA and industry reps tell DIA meeting.

Interchangeable Biosimilar Designations Shouldn't Be Forever, Innovators Say

US FDA may need to withdraw previous interchangeability determination due to new indications or manufacturing changes, reference product companies say; generic firms say prior interchangeability designation should apply to new indications absent significant scientific questions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel